Passage Bio to Present at Chardan’s 6th Annual Genetic Medicines Conference
PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) — Passage Bio, Inc. (NASDAQ:PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system (CNS) disorders, today announced that Simona King, chief financial officer of Passage Bio, will present at the upcoming Chardan Genetic Medicines Conference being held from October 3-4, 2022 in New York City.
Related news for (PASG)
- Passage Bio Reports First Quarter 2025 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Announces Interim Data from upliFT-D Study in FTD-GRN and Provides Business Updates
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights
- Passage Bio Reports Third Quarter 2024 Financial Results and Provides Recent Business Highlights